Liver toxicity in oncology trials and beyond: a simplified concept for management of hepatocellular drug-induced liver injury in patients with abnormal baseline liver tests

References

• Fontana RJ, Hayashi PH, Gu J, et al. Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset. Gastroenterology. 2014;147(1):96–108 e4. doi: 10.1053/j.gastro.2014.03.045
   PubMed Web of Science ®Google Scholar
• Larrey D, Pageaux GP. Drug-induced acute liver failure. Eur J Gastroenterol Hepatol. 2005;17(2):141–143. doi: 10.1097/00042737-200502000-00002
   PubMed Web of Science ®Google Scholar
• Lee WM. Drug-induced hepatotoxicity. N Engl J Med. 2003;349(5):474–485. doi: 10.1056/NEJMra021844
   PubMed Web of Science ®Google Scholar
• Lee WM. Drug-induced acute liver failure. Clin Liver Dis. 2013;17(4):575–586. viii. doi: 10.1016/j.cld.2013.07.001.
   PubMed Web of Science ®Google Scholar
• U.S. Department of health and human services, FDA, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance For Industry. Drug-Induced Liver Injury: Premarketing Clinical Evaluation. 2009 [cited 2022 Jan 20]. Available from: https://www.fda.gov/media/116737/download
   Google Scholar
• Dhanasekaran R, Kwo PY. The liver in oncology. Clin Liver Dis. 2017;21(4):697–707. doi: 10.1016/j.cld.2017.06.003
   PubMedGoogle Scholar
• Vincenzi B, Armento G, Spalato Ceruso M, et al. Drug-induced hepatotoxicity in cancer patients - implication for treatment. Expert Opin Drug Saf. 2016;15(9):1219–1238. doi: 10.1080/14740338.2016.1194824
   PubMed Web of Science ®Google Scholar
• Allison KH, Fligner CL, Parks WT. Radiographically occult, diffuse intrasinusoidal hepatic metastases from primary breast carcinomas: a clinicopathologic study of 3 autopsy cases. Arch Pathol Lab Med. 2004;128(12):1418–1423. doi: 10.5858/2004-128-1418-RODIHM
   PubMed Web of Science ®Google Scholar
• Diamond JR, Finlayson CA, Borges VF. Hepatic complications of breast cancer. Lancet Oncol. 2009;10(6):615–621. doi: 10.1016/S1470-2045(09)70029-4
   PubMed Web of Science ®Google Scholar
• Hampel PJ, Chaffee KG, King RL, et al. Liver dysfunction in chronic lymphocytic leukemia: prevalence, outcomes, and pathological findings. Am J Hematol. 2017;92(12):1362–1369. doi: 10.1002/ajh.24915
   PubMed Web of Science ®Google Scholar
• Kullak-Ublick GA, Merz M, Griffel L, et al. Liver safety assessment in special populations (hepatitis B, C, and oncology trials). Drug Saf. 2014;37 Suppl 1(S1):S57–S62. doi: 10.1007/s40264-014-0186-3
   PubMedGoogle Scholar
• Lee KW, Chan SL. Hepatotoxicity of targeted therapy for cancer. Expert Opin Drug Metab Toxicol. 2016;12(7):789–802. doi: 10.1080/17425255.2016.1190831
   PubMed Web of Science ®Google Scholar
• Lopez JB, Balasegaram M, Thambyrajah V, et al. The value of liver function tests in hepatocellular carcinoma. Malays J Pathol. 1996;18(2):95–99.
   PubMedGoogle Scholar
• Meunier L, Larrey D. Chemotherapy-associated steatohepatitis. Ann Hepatol. 2020;19(6):597–601. doi: 10.1016/j.aohep.2019.11.012
   PubMed Web of Science ®Google Scholar
• Prowell TM, Theoret MR, Pazdur R. Seamless oncology-drug development. N Engl J Med. 2016;374(21):2001–2003. doi: 10.1056/NEJMp1603747
   PubMed Web of Science ®Google Scholar
• Shantakumar S, Landis S, Lawton A, et al. Prevalence and incidence of liver enzyme elevations in a pooled oncology clinical trial cohort. Regul Toxicol Pharmacol. 2016;77:257–262. doi: 10.1016/j.yrtph.2016.03.019
   PubMed Web of Science ®Google Scholar
• Ulcickas Yood M, Bortolini M, Casso D, et al. Incidence of liver injury among cancer patients receiving chemotherapy in an integrated health system. Pharmacoepidemiol Drug Saf. 2015;24(4):427–434. doi: 10.1002/pds.3757
   PubMed Web of Science ®Google Scholar
• Regev A, Avigan MI, Kiazand A, et al. Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development. J Autoimmun. 2020;114:102514. doi: 10.1016/j.jaut.2020.102514
   PubMed Web of Science ®Google Scholar
• Council for international organizations of medical sciences (CIOMS), CIOMS working group on drug-induced liver injury (DILI): consensus report. Geneva; 2020 [cited 2022 Jun 28]. Available from: https://cioms.ch/publications/product/drug-induced-liver-injury/
   Google Scholar
• Ricart AD. Drug-induced liver injury in oncology. Ann Oncol. 2017;28(8):2013–2020. doi: 10.1093/annonc/mdx158
   PubMed Web of Science ®Google Scholar
• Kaplowitz N. Drug-induced liver injury. Clin Infect Dis. 2004;38 Suppl 2(Supplement_2):S44–8. doi: 10.1086/381446
   PubMedGoogle Scholar
• Aithal GP, Watkins PB, Andrade RJ, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther. 2011;89(6):806–815. doi: 10.1038/clpt.2011.58
   PubMed Web of Science ®Google Scholar
• Green RM, Flamm S. AGA technical review on the evaluation of liver chemistry tests. Gastroenterology. 2002;123(4):1367–1384. doi: 10.1053/gast.2002.36061
   PubMed Web of Science ®Google Scholar
• National Cancer Institute, Division of Cancer Treatment and Diagnosis. Common terminology criteria for adverse events (CTCAE). [cited 2022 Jul 12]. Available from: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm
   Google Scholar
• Chalasani N, Regev A. Drug-induced liver injury in patients with preexisting chronic liver disease in drug development: how to identify and manage? Gastroenterology. 2016;151(6):1046–1051. doi: 10.1053/j.gastro.2016.10.010
   PubMed Web of Science ®Google Scholar
• Regev A, Palmer M, Avigan MI, et al. Consensus: guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury during clinical trials in patients with nonalcoholic steatohepatitis. Aliment Pharmacol Ther. 2019;49(6):702–713. doi: 10.1111/apt.15153
   PubMed Web of Science ®Google Scholar
• Palmer M, Regev A, Lindor K, et al. Consensus guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury occurring during clinical trials in adults with chronic cholestatic liver disease. Aliment Pharmacol Ther. 2020;51(1):90–109. doi: 10.1111/apt.15579
   PubMed Web of Science ®Google Scholar
• Treem WR, Palmer M, Lonjon-Domanec I et al. Consensus guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury during clinical trials in adults with chronic viral hepatitis and adults with cirrhosis secondary to hepatitis B, C and Nonalcoholic Steatohepatitis. Drug Saf. 2020;44:133–165
   PubMed Web of Science ®Google Scholar
• Benes M. A possible use of the cubit rod in ancient Egypt to measure and draw lengths based on fractions. J Math Sci Adv Appl. 2021;67(1):85–93. doi: 10.18642/jmsaa_7100122234
   Google Scholar
• Dilling FS, Stricker I. Comparison: light rays and the intercept theorem in mathematics and physics education, In: Dilling FK, editor. Comparison of Mathematics and Physics Education II. MINTUS – Beiträge zur mathematisch-naturwissenschaftlichen Bildung. Wiesbaden:Springer Spektrum; 2022. p. 307–329.
   Google Scholar
• Zhou B, Sun C, Ahn D, et al. A novel passive tracking scheme exploiting geometric and intercept theorems. Sens (Basel). 2018;18(3). doi: 10.3390/s18030895
   Web of Science ®Google Scholar
• French D. The intercept theorem. In: French D, editor. Teaching and learning geometry. London (NY):Continuum International Publishing Group; 2004. p. 84–87.
   Google Scholar
• Seitz HK, Bataller R, Cortez-Pinto H, et al. Alcoholic liver disease. Nat Rev Dis Primers. 2018;4(1):16. doi: 10.1038/s41572-018-0014-7
   PubMed Web of Science ®Google Scholar
• Liu R, Pan X, Whitington PF. Increased hepatic expression is a major determinant of serum alanine aminotransferase elevation in mice with nonalcoholic steatohepatitis. Liver Int. 2009;29(3):337–343. doi: 10.1111/j.1478-3231.2008.01862.x
   PubMed Web of Science ®Google Scholar
• Qian K, Zhong S, Xie K, et al. Hepatic ALT isoenzymes are elevated in gluconeogenic conditions including diabetes and suppressed by insulin at the protein level. Diabetes Metab Res Rev. 2015;31(6):562–571. doi: 10.1002/dmrr.2655
   PubMed Web of Science ®Google Scholar